Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma
© von Delius et al; licensee BioMed Central Ltd. 2005
Received: 15 February 2005
Accepted: 12 June 2005
Published: 12 June 2005
Patients with advanced gallbladder and biliary tract carcinoma face a dismal prognosis, as no effective palliative chemotherapy exists. The antitumor effect of gemcitabine is schedule-dependent rather than dose-dependent. We evaluated the activity of a prolonged infusion of gemcitabine in advanced gallbladder and biliary tract carcinomas.
Nineteen consecutive eligible patients were enrolled. All patients were required to have histologically confirmed diagnosis and measurable disease. Gemcitabine was infused over 24 hours at a dose of 100 mg/m2 on days 1, 8, and 15. Treatment was repeated every 28 days until progression of disease or limiting toxicity. Tumor response was evaluated every second course by computed tomography (CT) scans.
Eighteen patients were evaluable for response. A total of 89 cycles of therapy were administered. One partial response was observed (6%; 95% confidence interval (CI): 0–27%) and ten additional patients had stable disease for at least two months (disease control rate 61%; 95% CI: 36–83%). The therapy was well tolerated, with moderate myelosuppression as the main toxicity. The median time to tumor progression and median overall survival was 3.6 months (95% CI 2.6–4.6 months) and 7.5 months (95% CI 6.5–8.5 months), respectively.
Weekly 24-hour gemcitabine at a dose of 100 mg/m2 is well tolerated. There was a relatively high rate of disease control for a median duration of 5.3 months (range 2.8–18.8 months). However, the objective response rate of this regimen in gallbladder and biliary tract carcinomas was limited.
Adenocarcinomas of the gallbladder and the biliary tract are relatively uncommon in the western world, with approximately 5,000 cases of gallbladder carcinoma and 2,500 cases of cholangiocarcinoma annually in the USA [1, 2]. Worldwide, the highest prevalence of gallbladder cancer is seen in Israel, Mexico, Chile, Japan, and among Native American women, particularly those living in New Mexico. Incidence of cholangiocarcinoma is highest in Israel, Japan, among Native Americans, and in Southeast Asia, where it can reach 87 per 100,000 .
Biliary tract tumors can occur anywhere in the hepatobiliary system. Cholangiocarcinoma may be further classified as intrahepatic or extrahepatic (hilar and distal bile duct) carcinomas. Hilar tumors, so called Klatskin's tumors, usually require partial liver resection for cure, whereas distal tumors may require pancreatectomy.
Gallbladder carcinoma has been linked to several risk factors. Gallstones, especially larger than 3 cm, chronic inflammation, bacterial infection, polyps, calcified (porcelain) gallbladder, ulcerative colitis, high energy and total carbohydrate intake, and high body mass index in women increase risk. Risk factors for cholangiocarcinoma are well understood, although most patients lack identifiable risks. Patients with primary sclerosing cholangitis, congenital choledochal cysts (most likely due to associated inflammation and bacterial infection), ulcerative colitis, exposure to carcinogens including cigarette smoke, hepatolithiasis, liver infection, hepatitis C, and biliary parasites carry an elevated risk .
Due to the lack of characteristic early symptoms, a definitive diagnosis of gallbladder and biliary tract carcinoma is often established at an advanced stage, and prognosis of patients with advanced tumors remains dismal. Even in patients undergoing aggressive surgery, the general outcome has been disappointing. Five-year survival rates are between 5–10% . Median survival of patients with advanced-stage disease is in the range of only a few months. Due to the lack of randomized phase III studies there is no standard regimen for palliative chemotherapy of gallbladder and biliary tract carcinomas. Depending on the patient's general condition best supportive care, a clinical trial, 5-FU, or gemcitabine is recommended according to guidelines of the National Comprehensive Cancer Network.
Gemcitabine is phosphorylated by deoxycytidine kinase into the active metabolite gemcitabine triphosphate (GemTP). The rate-limiting step in the formation of GemTP is the phosphorylation of gemcitabine to the monophosphate by deoxycytidine kinase . The diphosphate is a potent inhibitor of ribonucleotide reductase, an action that reduces deoxynucleotide pools. Decreased cellular concentrations of deoxycytidine triphosphates permit a more rapid phosphorylation of gemcitabine and decrease the metabolic clearance of gemcitabine nucleotides. As a consequence of this, the active nucleotide forms of gemcitabine are effectively accumulated to high concentrations in the cell .
According to the rate-limited activation of gemcitabine a schedule-dependent antitumor effect of gemcitabine was found in various in vivo model systems in preclinical studies  suggesting slower infusion rates in the clinical setting. Furthermore, the treatment of mice bearing the colon 26–10 murine colon carcinoma was considerably more effective by applying a weekly 24-hour schedule .
Based on the results of a pilot study  and a phase II study in patients with pancreatic adenocarcinoma  we started a phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma.
To be eligible for the trial, patients were required to have histologically confirmed, irresectable or metastatic carcinoma of the gallbladder or biliary tract. Patients had to have measurable disease on a computed tomography (CT) scan or magnetic resonance imaging (MRI) and had to have a performance status (WHO) ≤ 2. Patients were allowed to have received one previous chemotherapy, but no previous treatment with gemcitabine. They also met the following laboratory criteria: serum bilirubin value ≤ two times upper normal limit, leukocyte count ≥ 3.0 × 109/L, platelet count ≥ 100 × 109/L, and serum creatinine ≤ 2.0 mg/dL.
Patients with active infections, unstable cardiovascular conditions, brain metastases, or other serious medical illnesses were excluded from this trial.
Informed consent was obtained from all patients included in the study, which was approved by local ethics committees.
Therapy was administered on an outpatient basis and patients were premedicated with appropriate antiemetics.
Patients received gemcitabine (100 mg/m2) as a 24-hour intravenous (i.v.) infusion. Treatments were repeated every week for three consecutive weeks followed by one week of rest; a full cycle consisted of four weeks.
Doses were modified according to the following criteria: The weekly gemcitabine dose was reduced by 25% for patients whose leukocyte count was ≤ 2.5–3.0 × 109/mL, whose platelet count was ≥ 75–100 × 109/L, or if grade 2 nonhematologic toxicity was present. The weekly dose was reduced by 50% for patients whose leukocyte count was ≤ 2.0–2.5 × 109/L or whose platelet platelet count was ≥ 50–75 × 109/L. The weekly dose was omitted if the leukocyte count was less than 2.0 × 109/L, platelet count was less than 50 × 109/L, or grade 3 nonhematologic toxicity was present.
Weekly blood counts were obtained to determine the level of myelosuppression. Before each cycle a full clinical evaluation noting the performance status and a physical exam were performed and a complete chemistry panel was obtained. In addition, CA19-9 levels were measured every eight weeks.
The antitumor response was evaluated every eight weeks by CT or MRI, unless signs of progression were evident. In terms of response RECIST criteria  were applied, since in most cases of these tumors interpretation of bi-dimensional measurements is complicated by associated inflammation and/or necrosis, as well as anatomical structures in the vicinity. Complete response was defined as the disappearance of all signs and symptoms of disease. Partial response was defined as a decrease of > 30 % of the sum of the largest diameters of target (= measurable) lesions without appearance of new lesions or progression of non-target (= evaluable) lesions. To be assigned a status of response, changes in tumor measurement were confirmed by repeat assessment that was performed no less than 4 weeks after the criteria for response were first met. Stable disease was defined as no sufficient shrinkage to qualify for partial response or less than a 20% increase in the sum of the largest diameters of target lesions without appearance of new lesions or progression of non-target lesions. Progressive disease was defined as a 20% increase in the sum of the largest diameters of target lesions or as appearance of new lesions or as progression of non-target lesions.
The response was validated by radiologists independent of the study.
Disease control was defined as the absence of tumor progression (i.e. complete and partial response and stable disease) for at least two months.
The primary end point of this trial was objective response. Secondary end points included progression free survival, overall survival, and toxicity.
Simon's optimal two-stage design was used for calculation of the sample size . Early stopping rules were provided to allow for study discontinuation in the event of lack of efficacy. Sufficient responses (greater than 2 in 18 evaluable patients) were required to trigger the second phase of enrollment for another 17 for a maximum of 35 patients. 95% confidence interval was calculated by the method of Clopper and Pearson. Correlations are nonparametric by the method of Spearman. Progression free survival and overall survival were calculated from the start of chemotherapy until progression, death or last follow-up by the Kaplan-Meier method using SPSS, version 12.0 software.
Patient characteristics of all patients enrolled.
Total no. of patients (evaluable for response)
Age, median (range)
Performance status (WHO)
Intrahepatic bile ducts
Extrahepatic bile ducts
Site of metastasis
Recurrence after previous surgical resection
Pre-treatment requiring stent or percutaneous transhepatic drainage because of obstructive jaundice
Total bilirubin (mg/dl)
Gamma-glutamyltransferase (<66 U/La)
Aspartate aminotransferase (10–50 U/la)
CA19-9 (<32 U/mLa)
Treatment-related toxicities of all 19 patients enrolled.
Number of patients (%)
Response and Survival
No complete response was observed. One of the 18 evaluable patients (6%; 95%CI: 0–27%) with a gallbladder carcinoma had a partial response. Ten additional patients had stable disease for a median duration of 5.3 months (range 2.8–18.8 months) resulting in a disease control rate of 61% (95%CI: 36–83%). Two of these patients had gallbladder carcinoma, four intrahepatic cholangiocarcinoma, and four extrahepatic cholangiocarcinoma. Seven (39%, 95%CI: 17–64%) patients had stable disease after 4 cycles of chemotherapy.
In fourteen of seventeen patients (82%) assessed baseline CA19-9 levels were elevated (median 581, mean 98,849, range 115–1,244,000; normal < 32 U/mL). In eleven patients follow-up values were obtained. Ten of these eleven patients had elevated baseline levels. There was a significant negative correlation (r = -0.65, p = 0.032) between relative changes of CA19-9 during chemotherapy compared with baseline and progression free survival.
In this phase II trial of a prolonged infusion of gemcitabine for advanced gallbladder and biliary tract carcinoma we only found a 6% objective response rate (95%CI: 0–27%). According to the early stopping rules accrual was terminated after enrollment of 19 patients, thereof 18 evaluable for response. Disease control for at least two months was observed in 11 patients (61%, 95%CI: 36–83%) for a median duration of 5.3 months (range 2.8–18.8 months). As expected there was a significant correlation of progression free and overall survival. Toxicity was generally mild with myelosuppression as the major toxicity.
Only relatively small phase II trials have assessed the efficacy and toxicity profiles of chemotherapy regimens in the palliative treatment of gallbladder cancer and cholangiocarcinoma. Due to tumor-specific complications such as obstructive jaundice with impaired hepatic metabolism and biliary excretion toxicity profiles of chemotherapy regimens may be different in gallbladder and biliary tract carcinoma compared to other cancers. Single-agent and multiagent regimens have yielded modest results in patients with advanced biliary carcinomas. Overall response rates and disease control rates are about 25% (mostly 13–35%, range 0–64%) and about 65% (mostly 55–72%, range 19–94%), respectively .
Among several different new anticancer drugs, gemcitabine has generated particular interest. Considered as standard treatment for advanced pancreatic carcinoma  and given the histogenetic affinity between the pancreas and the biliary tract, a number of phase II trials of gemcitabine with differing results were conducted in patients with advanced gallbladder and biliary tract cancers. Patients mostly received gemcitabine at a dose of 1000 mg/m2 over 30 minutes.
Possible options to further improve the therapeutic efficacy of gemcitabine monotherapy include modifications of the administration schedule. Tempero et al.  found improved activity of gemcitabine 1500 mg/m2 as a fixed dose rate infusion of 10 mg/m2/min in comparison to high dose gemcitabine (2200 mg/m2) infusion over 30 minutes in pancreatic cancer. Pharmacokinetic analysis in this study also revealed significantly higher concentrations of intracellular gemcitabine triphosphate with the prolonged infusion. However, grade 3–4 hematologic toxicity occurred in up to almost 50% in the fixed dose rate arm. In contrast, in our trial of 24-hour gemcitabine at a dose of 100 mg/m2 toxicity was mild.
Selection of phase II studies of gemcitabine in advanced biliary tract cancer.
Number of assessable patients
Metzger et al (16)
Verderame et al (17)
Gebbia et al (18)
Penz et al (19)
Lin et al (20)
Tsavaris et al (22)
Park et al (23)
In conclusion, weekly 24-hour infusion of gemcitabine at a dose of 100 mg/m2 in patients with advanced gallbladder and biliary tract carcinoma can be safely administered in an outpatient setting. A relatively high disease control rate was observed in this trial. However, in terms of objective response antitumor activity was only marginal. Therefore, gemcitabine as continuous infusion seems not to be superior to gemcitabine administered in short term.
- De Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM: Biliary tract cancers. N Engl J Med. 1999, 341: 1368-78. 10.1056/NEJM199910283411807.View ArticlePubMedGoogle Scholar
- Gores GJ: Cholangiocarcinoma: current concepts and insights. Hepatology. 2003, 5: 961-9. 10.1053/jhep.2003.50200.View ArticleGoogle Scholar
- Rajagopalan V, Daines WP, Grossbard ML, Kozuch P: Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1. Oncology (Huntingt). 2004, 18: 889-96.Google Scholar
- Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W: Pharmacollogically directed design of the dose rate and schedule of 2, 2-dideoxy-fluorocytidine (Gemcitabine) administration in leukemia. Cancer Res. 1990, 50: 6823-6.PubMedGoogle Scholar
- Plunkett W, Huang P, Searcy CE, Gandhi V: Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol. 1996, 23: 3-15.PubMedGoogle Scholar
- Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ: Schedule-dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol. 1995, 22: 42-6.PubMedGoogle Scholar
- Veerman G, Ruiz van Haperen VW, Vermorken JB, Noordhuis P, Braakhuis BJ, Pinedo HM, Peters GJ: Antitumor activity of prolonged as compared with bolus administration of 2, 2-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol. 1996, 38: 335-42. 10.1007/s002800050492.View ArticlePubMedGoogle Scholar
- Eckel F, Lersch C, Assmann G, Schulte-Frohlinde E: Toxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: A pilot study. Cancer Invest. 2002, 20 (2): 180-5. 10.1081/CNV-120014881.View ArticlePubMedGoogle Scholar
- Eckel F, Schmelz R, Erdmann J, Mayr M, Lersch C: Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma. Cancer Invest. 2003, 21: 690-4. 10.1081/CNV-120023767.View ArticlePubMedGoogle Scholar
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000, 92 (3): 205-16. 10.1093/jnci/92.3.205.View ArticlePubMedGoogle Scholar
- Simon R: Optimal two-stage designs for phase II clinical trials. Controlled Clinical trials. 1989, 10: 1-10. 10.1016/0197-2456(89)90015-9.View ArticlePubMedGoogle Scholar
- Eckel F, Lersch C, Assmann G, Schulte-Frohlinde E: Phase II trial of low-dose cyclophosphamide, leucovorin, high-dose 5-fluorouracil 24-hour continuous infusion and tamoxifen in advanced biliary tract cancer. Ann Oncol. 2000, 11: 762-3. 10.1023/A:1008368611993.View ArticlePubMedGoogle Scholar
- Daines WP, Rajagopalan V, Grossbard ML, Kozuch P: Gallbladder and biliary tract carcinoma: A comprehensive update, Part 2. Oncology (Huntingt). 2004, 18: 1049-59.Google Scholar
- Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997, 15: 2403-13.PubMedGoogle Scholar
- Tempero M, Plunkett W, Ruiz van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J: Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003, 21 (18): 3402-8. 10.1200/JCO.2003.09.140.View ArticlePubMedGoogle Scholar
- Metzger J, Sauerbruch T, Ko Y, et al: A phase II trial of gemcitabine in gallbladder and biliary tract carcinomas. Onkologie. 1998, 21: 232-4. 10.1159/000026821.Google Scholar
- Verderame F, Mandina P, Abruzzo F, Scarpulla M, Di Leo R: Biliary tract cancer: our experience with gemcitabine treatment. Anticancer Drugs. 2000, 11 (9): 707-8. 10.1097/00001813-200010000-00006.View ArticlePubMedGoogle Scholar
- Gebbia V, Giuliani F, Maiello E, Colucci G, Verderame F, Borsellino N, Mauceri G, Caruso M, Tirrito ML, Valdesi M: Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol. 2001, 19 (20): 4089-91.PubMedGoogle Scholar
- Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, Depisch D, Krauss G, Schneeweiss B, Scheithauer W: Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol. 2001, 12 (2): 183-6. 10.1023/A:1008352123009.View ArticlePubMedGoogle Scholar
- Lin MH, Chen JS, Chen HH, Su WC: A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy. 2003, 49 (3): 154-8. 10.1159/000070622.View ArticlePubMedGoogle Scholar
- Eng C, Ramathan RK, Wong MK, Remick SC, Dai L, Wade-Oliver KT, Mani S, Kindler HL: A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol. 2004, 27 (6): 565-9. 10.1097/01.coc.0000135924.94955.16.View ArticlePubMedGoogle Scholar
- Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D, Tsipras H, Margaris H, Papastratis G, Tzima E, Papadoniou N, Karatzas G, Papalambros E: Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs. 2004, 22 (2): 193-8. 10.1023/B:DRUG.0000011797.09549.53.View ArticlePubMedGoogle Scholar
- Park JS, Oh SY, Kim SH, Kwon HC, Kim JS, Jin-Kim H, Kim YH: Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol. 2005, 35 (2): 68-73. 10.1093/jjco/hyi021.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/5/61/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.